2023 World Conference on Lung Cancer (Posters)-EP06.03. Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement

EP06.03. Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement - PDF(Slides)

Back to course

Pdf Summary

This study aimed to analyze the frequency of EGFR mutation and ALK gene rearrangement in adenosquamous cell carcinoma (ASC) of the lung in Korean patients. ASC is a rare subtype of non-small cell carcinoma characterized by a mixture of squamous cell carcinoma and adenocarcinoma cells. Patients with ASC have a poor prognosis and aggressive disease. EGFR-TKIs and ALK inhibitors have shown efficacy in treating patients with EGFR-TKI-sensitive mutations or ALK rearrangement. However, there is limited literature on the frequency of these genetic alterations in ASC.<br /><br />The study included 28 patients with ASC who underwent surgical resection or biopsy at a single center in Korea between 2012 and 2021. The diagnosis and differentiation of ASC were confirmed by institutional pathologists. The researchers analyzed the tumor samples for EGFR mutation and ALK rearrangement using molecular testing methods.<br /><br />The results showed that EGFR mutations were detected in 17.9% of the patients, with two cases having an exon 19 deletion, two cases having a L858R mutation, and one case having an exon 21 mutation. No T790M mutations, which are associated with resistance to EGFR-TKIs, were found. ALK rearrangement was observed in 7% of the cases.<br /><br />These findings suggest that EGFR mutations occur in ASC at lower percentages compared to conventional adenocarcinoma in the Asian population. ALK rearrangement is less common in ASC. The detection of these somatic mutations, including EGFR and ALK, is clinically important as it can guide the selection of targeted treatment options such as EGFR-TKIs and ALK inhibitors.<br /><br />In conclusion, this study provides insights into the frequency of EGFR mutation and ALK rearrangement in ASC of the lung in Korean patients. Molecular testing for these genetic alterations is crucial for identifying patients who may benefit from targeted therapies. Further research is needed to better understand the molecular characteristics and treatment options for ASC.

Asset Subtitle

Goohyeon Hong

Meta Tag

Speaker Goohyeon Hong

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

EGFR mutation

ALK gene rearrangement

adenosquamous cell carcinoma

lung

Korean patients

non-small cell carcinoma

squamous cell carcinoma

adenocarcinoma cells

EGFR-TKIs

ALK inhibitors